Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 12/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375677 | 1.00 | LTA4H (0.56) | LTA4HSLC1A1SLC1A3SLC1A2S1PR1 | |
| SCHEMBL27840732 | 0.92 | LTA4H (0.56) | LTA4HSLC1A1SLC1A3SLC1A2S1PR1 | |
| SCHEMBL27840730 | 0.92 | LTA4H (0.56) | LTA4HSLC1A1SLC1A3SLC1A2S1PR1 | |
| SCHEMBL2307636 | 0.92 | LTA4H (0.58) | LTA4HSLC1A1S1PR1BACE1 | |
| SCHEMBL6286329 | 0.88 | LTA4H (0.55) | LTA4HSLC1A1S1PR1BACE1NPC1 | |
| SCHEMBL1372073 | 0.87 | S1PR1 (0.62) | LTA4HS1PR1 | |
| SCHEMBL1372965 | 0.87 | LTA4H (0.75) | LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1372071 | 0.87 | S1PR1 (0.62) | LTA4HS1PR1 | |
| SCHEMBL1372962 | 0.87 | LTA4H (0.75) | LTA4HNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27228895 | 0.84 | SLC1A1 (0.56) | LTA4HSLC1A1PPARACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | LTA4H 1113/4885SLC1A1 3570/4885SLC1A3 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.